Results 241 to 250 of about 790,096 (261)

Outlook For Biosimilar Molecules Entering Croatian Pharmaceutical Market In The Period From 2016 To 2020

Clinical Therapeutics, 2016
R, Likic, I, Simic, V, Erdeljic Turk, K, Makar-Ausperger, M, Radacic-Aumiler, I, Cegec, D, Juricic Nahal, I, Kraljickovic   +7 more
openaire   +2 more sources

The Effect of Biosimilar Prescription Targets for Erythropoiesis-Stimulating Agents on the Prescribing Behavior of Physicians in Germany

Value in Health, 2022
Katharina E Blankart, Benjamin Birkner
exaly  

Clinical safety of biosimilar recombinant human erythropoietins

Expert Opinion on Drug Safety, 2012
Karen M MacDonald, Ivo Abraham
exaly  

Clinical safety of biosimilar recombinant human granulocyte colony-stimulating factors

Expert Opinion on Drug Safety, 2013
Karen M MacDonald, Ivo Abraham
exaly  

Economics as a guide to developing public policies for biosimilar pharmaceutical products

Queen Mary Journal of Intellectual Property, 2012
openaire   +1 more source

Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries

European Journal of Health Economics, 2014
Márta Péntek, Valentin Brodszky, Petra Baji   +2 more
exaly  

A survey of global biosimilar implementation practice conducted by the International Society of Oncology Pharmacy Practitioners

Journal of Oncology Pharmacy Practice, 2020
Emma Foreman, Himanshu Patel
exaly  

Biosimilar Filgrastim Uptake And Costs Among Commercially Insured, Medicare Advantage

Health Affairs, 2019
Daniel J Weisdorf, Ronald S Go, Molly Moore Jeffery   +2 more
exaly  

Comparative Stability Studies of Different Infliximab and Biosimilar CT-P13 Clinical Solutions by Combined Use of Physicochemical Analytical Techniques and Enzyme-Linked Immunosorbent Assay (ELISA)

BioDrugs, 2019
J. Hermosilla, R. Sánchez-Martín, R. Pérez-Robles, A. Salmerón-García, S. Casares, J. Cabeza, L. Cuadros-Rodríguez, N. Navas   +7 more
semanticscholar   +1 more source

Demonstration of Pharmacokinetic and Pharmacodynamic Equivalence in Healthy Volunteers for B12019, a New Proposed Pegfilgrastim Biosimilar Free

Blood, 2016
Dirk Lehnick
exaly